Assembly Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 21, 2026, details a material definitive agreement entered into by Assembly Biosciences, Inc. (ASMB). The report covers an underwritten registered offering of common stock and pre-funded warrants, with the offering closing on May 26, 2026.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 3,358,602 shares of Common Stock at $26.50 per share and 415,000 Pre-Funded Warrants at $26.499 per warrant.
- Option Exercise: Underwriters exercised their 30-day option in full on May 22, 2026, to purchase an additional 566,040 shares of Common Stock.
- Net Proceeds: The Company received approximately $107.4 million in net proceeds from the Offering and the Option Exercise, after deducting underwriting discounts, commissions, and estimated offering expenses.
- Underwriters: Guggenheim Securities, LLC and UBS Securities LLC served as representatives.
Material Changes and Terms
The filing reports a significant increase in liquidity through the capital raise. Key terms include:
- Lock-Up Agreements: Executive officers and directors agreed not to sell shares for 90 days following the filing of the final prospectus supplement.
- Pre-Funded Warrants: These warrants have an initial exercise price of $0.001 per share, are immediately exercisable, and have no termination date. Beneficial ownership is capped at 4.99% unless a holder provides 61 days' notice to increase the threshold to 9.99% or 19.99%.
- Registration: The offering was conducted pursuant to an effective Form S-3 filed on March 19, 2026.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding future operations beyond the transaction details. The primary risk noted is the customary indemnification of underwriters against liabilities incurred in connection with the Offering. The text does not provide clear values for current revenue, profit, cash flow, or debt levels outside of the transaction proceeds.
Investor Verification Checklist
- Verify the final closing date of May 26, 2026, and confirm the total number of shares issued including the option exercise.
- Review the definitive Underwriting Agreement (Exhibit 1.1) for specific details on underwriting discounts and commissions deducted from the $107.4 million net proceeds.
- Confirm the impact of the new share issuance on existing shareholder dilution.
- Check the press releases (Exhibits 99.1 and 99.2) for any additional strategic use of proceeds not detailed in the 8-K text.